| Impairment |
| Symptoms | ≤ 2 days per week | > 2 days per week, but not daily | Daily | Throughout the day |
| Nighttime awakenings | ≤ 2 times per month | 3 to 4 times per month | > Once per week, but not nightly | Often 7 times per week |
| Short-acting beta agonist use for symptom control (not for prevention of exercise-induced bronchospasm) | ≤ 2 days per week | > 2 days per week, but not more than once per day | Daily | Several times per day |
| Interference with normal activity | None | Minor limitation | Some limitation | Extremely limited |
| Lung function | Normal FEV1 between exacerbations; FEV1 >80 percent of predicted; FEV1/FVC normal | FEV1 ≥ 80 percent of predicted; FEV1/FVC normal | FEV1 > 60 percent but < 80 percent of predicted; FEV1/FVC reduced 5 percent | FEV1 < 60 percent of predicted; FEV1/FVC reduced >5 percent |
| Risk |
| Exacerbations requiring oral systemic corticosteroids | 0 to 1 per year† | ≥ 2 per year† | ≥ 2 per year† | ≥ 2 per year† |
| Consider severity and interval since last exacerbation; frequency and severity may fluctuate over time for patients in any severity category; relative annual risk of exacerbations may be related to FEV1 |